Press Releases Entera Bio Ltd.

Equities

ENTX

IL0011429839

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.25 ^USD	-2.60%		-3.02%	+275.00%

May. 15	Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	CI
May. 13	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	May. 15	AQ
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024	May. 13	AQ
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates	May. 10	AQ
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research	Apr. 08	AQ
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months	Mar. 26	AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	AQ
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates	Mar. 08	AQ
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement	Mar. 04	AQ
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Jan. 30	AQ
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule	Jan. 03	AQ
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025	Dec. 26	AQ
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform	Nov. 29	AQ
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development	Nov. 14	AQ
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis	Nov. 09	AQ
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting	23-10-16	AQ
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes	23-09-12	AQ
Entera Bio to Participate in Upcoming Investor Conferences	23-09-05	AQ
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting	23-08-16	AQ
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates	23-08-11	AQ
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors	23-06-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Entera Bio Ltd.

Equities

ENTX

IL0011429839

Press Releases

Filters